US 12,280,039 B2
Cancer vaccine compositions and methods of use thereof
Terry Opgenorth, Fort Collins, CO (US); Amanda Guth, Fort Collins, CO (US); and Raymond Goodrich, Fort Collins, CO (US)
Assigned to Colorado State University Research Foundation, Fort Collins, CO (US)
Appl. No. 16/982,887
Filed by Colorado State University Research Foundation, Fort Collins, CO (US)
PCT Filed Mar. 21, 2019, PCT No. PCT/US2019/023320
§ 371(c)(1), (2) Date Sep. 21, 2020,
PCT Pub. No. WO2019/183320, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/755,741, filed on Nov. 5, 2018.
Claims priority of provisional application 62/688,051, filed on Jun. 21, 2018.
Claims priority of provisional application 62/645,975, filed on Mar. 21, 2018.
Prior Publication US 2021/0000936 A1, Jan. 7, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 31/138 (2006.01); A61K 31/4178 (2006.01); A61K 31/525 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 47/26 (2006.01); A61N 5/06 (2006.01)
CPC A61K 31/4178 (2013.01) [A61K 31/138 (2013.01); A61K 31/525 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 47/26 (2013.01); A61N 5/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/5152 (2013.01); A61N 2005/0661 (2013.01)] 19 Claims
 
1. A cancer vaccine composition comprising inactivated cancer cells and an adjuvant;
wherein the cancer cells are inactivated by treating them with UV light comprising a wavelength of 310 nm to 320 nm in the presence of riboflavin;
wherein the structure of one or more antigenic proteins on the cancer cells is not destroyed by the treatment with UV light;
wherein the DNA of the inactivated cancer cells comprises oxidized guanine bases;
wherein the cell membrane integrity and/or the nuclear membrane integrity of the inactivated cancer cells is not compromised; and
wherein the adjuvant comprises a toll-like receptor 9 (TLR9) agonist.